Prognostic and predictive value of EGFR and EGFR-ligands in blood of breast cancer patients: a systematic review
Open Access
- 1 December 2017
- journal article
- review article
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 56 (5) , 688-701
Abstract
Epidermal growth factor receptor (EGFR) serves as a co-target for dual/pan-EGFR-inhibitors in breast cancer. Findings suggest that EGFR and EGFR-ligands are involved in resistance towards certain breast cancer treatments. The aim is to explore the validity of EGFR and EGFR-ligands in blood as prognostic and predictive biomarkers in breast cancer. The systematic review was conducted in accordance to the PRISMA guidelines. Literature searches were conducted to identify publications exploring correlations between EGFR/EGFR-ligands in serum/plasma of breast cancer patients and prognostic/predictive outcome measures. Sixteen publications were eligible for inclusion. Twelve studies evaluated EGFR, whereas five studies evaluated one or more of the EGFR-ligands. Current evidence indicates associations between low baseline serum-EGFR and shorter survival or reduced response to treatment in patients with advanced breast cancer, especially in patients with estrogen and/or progesterone receptor positive tumors. The prognostic and predictive value of EGFR and EGFR-ligands in blood has only been investigated in highly selected subsets of breast cancer patients and most studies were small. This is the first systematic review evaluating the utility of EGFR and EGFR-ligands as predictive and prognostic biomarkers in blood in breast cancer. Further exploration in large well-designed studies is needed.Keywords
This publication has 50 references indexed in Scilit:
- Monocytes/macrophages support mammary tumor invasivity by co-secreting lineage-specific EGFR ligands and a STAT3 activatorBMC Cancer, 2013
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Adjuvant Trastuzumab in HER2-Positive Breast CancerNew England Journal of Medicine, 2011
- Mechanisms of Endocrine Resistance in Breast CancerAnnual Review of Medicine, 2011
- HER-2 positive breast cancer: decreasing proportion but stable incidence in Finnish population from 1982 to 2005Breast Cancer Research, 2009
- The multiplex bead array approach to identifying serum biomarkers associated with breast cancerBreast Cancer Research, 2009
- Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer patientsBreast Cancer Research, 2007
- Serum EGFR and serum HER‐2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapyCancer, 2007
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogeneScience, 1987